3 Generic Drug Maker, Zinc Oxide and Basmati Stocks With a Strong Future Roadmap: Aurobindo Pharma, JG Chemicals and LT Foods
- October 16, 2026
- Posted by: Neeraj Pandey
- Category: Best Stocks
Aurobindo Pharma Rs 1,677.90, P/E 25.46. JG Chemicals Rs 629.45, P/E 31.94. LT Foods Rs 419.60, P/E 21.98. Closing prices of 14 Oct 2026.
Quick Answer
Generic drug maker, zinc oxide and basmati stocks with the clearest long-term roadmaps today include Aurobindo Pharma in generic formulations and active ingredients sold in the US, Europe and emerging markets, JG Chemicals in zinc oxide used in tyres, ceramics, paints and other industrial products and LT Foods in basmati rice and packaged foods sold under brands such as Daawat. FY26 revenue growth was 5.6% at Aurobindo Pharma, 15.2% at JG Chemicals and 25.7% at LT Foods. P/E stands at 25.46 for Aurobindo Pharma (industry 37.59), 31.94 for JG Chemicals (industry 36.60) and 21.98 for LT Foods (industry 34.85). Demand cycles, input costs and valuation decide how much of that growth the market keeps paying for, so each company’s risks need equal attention.
Generic drug maker, zinc oxide and basmati stocks give investors exposure to medicines, industrial chemicals and food staples sold at home and abroad. Volumes, export demand and margins decide how much of that demand turns into profit.
Readers comparing generic drug maker, zinc oxide and basmati stocks should weigh growth, margins, cash flow and valuation together instead of leaning on any single number.
This list covers three generic drug maker, zinc oxide and basmati stocks: Aurobindo Pharma for generic formulations and active ingredients sold in the US, Europe and emerging markets, JG Chemicals for zinc oxide used in tyres, ceramics, paints and other industrial products and LT Foods for basmati rice and packaged foods sold under brands such as Daawat. Every figure comes from the latest reported financials and the 14 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Generic Drug Maker, Zinc Oxide and Basmati Stocks?
Generic drug maker, zinc oxide and basmati stocks are shares of companies that make health products, chemicals or run restaurants. Results depend on volumes, store additions and margins, so margins and cash flow separate the stronger names.
Generic Drug Maker, Zinc Oxide and Basmati Stocks at a Glance
The table compares size, valuation, return on equity and debt for the three generic drug maker, zinc oxide and basmati stocks as of the 14 Oct 2026 close.
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE | Debt to Equity |
|---|---|---|---|---|---|---|
| Aurobindo Pharma | 1,677.90 | 94,477 | 25.46 | 37.59 | 9.25% | 0.21 |
| JG Chemicals | 629.45 | 2,505 | 31.94 | 36.60 | 12.47% | 0.01 |
| LT Foods | 419.60 | 14,072 | 21.98 | 34.85 | 13.83% | 0.36 |
Among healthcare, chemicals and consumer stocks, all three trade at a discount to their industry P/E multiples.
Why Do Generic Drug Maker, Zinc Oxide and Basmati Stocks Have a Strong Roadmap in India?
Generic drug maker, zinc oxide and basmati stocks have a strong roadmap in India because global demand for generic medicines, tyre and paint output and premium rice exports keep adding volumes for these firms. Three drivers stand out.
- Generic exports: Regulated markets buy affordable generic medicines.
- Industrial demand: Tyres, ceramics and paints use zinc oxide.
- Premium food: Shoppers choose branded basmati at home and abroad.
Aurobindo Pharma: Generic Formulations and Ingredients Build the Next Leg
Aurobindo Pharma’s roadmap rests on generic formulations and active ingredients sold in the US, Europe and emerging markets, with a wide product basket supporting export revenue.
Revenue grew from Rs 23,775.84 crore in FY22 to Rs 34,145.17 crore in FY26, a 43.6% rise, and FY26 revenue was 5.6% higher than FY25. FY26 net profit rose 0.6% to Rs 3,502.97 crore. Over four years, net profit rose from Rs 2,647.11 crore in FY22 to Rs 3,502.97 crore. In Q1 FY27, revenue grew 18.1% to Rs 9,414.58 crore, and net profit rose 25.2% to Rs 1,032.03 crore. Operating margin was 21.61% in FY26 and 23.10% in Q1 FY27 against 21.95% a year earlier.
Debt to equity is 0.21 and return on equity is 9.25%. FY26 operating cash flow was Rs 5,526.37 crore against capital expenditure of Rs 3,104.67 crore. Aurobindo Pharma paid a dividend of Rs 4 per share for FY26, a yield of 0.25%. At a P/E of 25.46 against an industry P/E of 37.59, the stock trades below its industry multiple.
What to watch: Q1 FY27 operating margin was 23.10% against 21.61% for FY26, so margin stability is the figure to follow as volumes grow.
JG Chemicals: Zinc Oxide Demand Builds the Next Leg
JG Chemicals’ roadmap rests on zinc oxide used in tyres, ceramics, paints and other industrial products, with steady industrial demand supporting volumes.
Revenue grew from Rs 623.05 crore in FY22 to Rs 988.77 crore in FY26, a 58.7% rise, and FY26 revenue was 15.2% higher than FY25. FY26 net profit rose 2.8% to Rs 68.65 crore. Over four years, net profit rose from Rs 43.13 crore in FY22 to Rs 68.65 crore. In Q1 FY27, revenue grew 43.8% to Rs 318.38 crore, and net profit rose 59.7% to Rs 26.12 crore. Operating margin was 10.09% in FY26 and 11.48% in Q1 FY27 against 10.65% a year earlier.
Debt to equity is 0.01 and return on equity is 12.47%. FY26 operating cash flow was Rs 43.57 crore against capital expenditure of Rs 39.03 crore. The dividend yield is 0.16%. At a P/E of 31.94 against an industry P/E of 36.60, the stock trades below its industry multiple.
What to watch: Q1 FY27 operating margin was 11.48% against 10.09% for FY26, so margin stability is the figure to follow as volumes grow.
LT Foods: Basmati and Packaged Foods Anchor the Roadmap
LT Foods’ roadmap rests on basmati rice and packaged foods sold under brands such as Daawat, with exports and branded sales supporting revenue.
Revenue grew from Rs 5,450.58 crore in FY22 to Rs 11,023.06 crore in FY26, a 102.2% rise, and FY26 revenue was 25.7% higher than FY25. FY26 net profit rose 2.2% to Rs 625.38 crore. Over four years, net profit rose from Rs 309.20 crore in FY22 to Rs 625.38 crore. In Q1 FY27, revenue grew 26.4% to Rs 3,161.29 crore, and net profit rose 8.9% to Rs 183.45 crore. Operating margin was 11.35% in FY26.
Debt to equity is 0.36 and return on equity is 13.83%. FY26 operating cash flow was Rs 910.50 crore against capital expenditure of Rs 359.62 crore. LT Foods paid a dividend of Rs 3 per share for FY26, a yield of 0.74%. At a P/E of 21.98 against an industry P/E of 34.85, the stock trades below its industry multiple.
What to watch: The P/E of 21.98 against an industry P/E of 34.85 leaves valuation less stretched, so the next quarters’ growth is the figure to follow.
Best Generic Drug Maker, Zinc Oxide and Basmati Stocks in India: Aurobindo Pharma vs JG Chemicals vs LT Foods on Key Financials
Among the best generic drug maker, zinc oxide and basmati stocks in India, Aurobindo Pharma leads on FY26 operating margin; JG Chemicals leads on Q1 FY27 revenue growth and Q1 FY27 net profit growth; LT Foods leads on FY26 revenue growth and return on equity. The table puts the numbers side by side.
| Metric | Aurobindo Pharma | JG Chemicals | LT Foods |
|---|---|---|---|
| FY26 revenue (Rs Cr) | 34,145.17 | 988.77 | 11,023.06 |
| FY26 revenue growth | 5.6% | 15.2% | 25.7% |
| FY26 net profit (Rs Cr) | 3,502.97 | 68.65 | 625.38 |
| FY26 net profit growth | 0.6% | 2.8% | 2.2% |
| FY26 operating profit margin | 21.61% | 10.09% | 11.35% |
| Q1 FY27 revenue growth (YoY) | 18.1% | 43.8% | 26.4% |
| Q1 FY27 net profit growth (YoY) | 25.2% | 59.7% | 8.9% |
| Return on equity | 9.25% | 12.47% | 13.83% |
| P/E ratio | 25.46 | 31.94 | 21.98 |
| Debt to equity | 0.21 | 0.01 | 0.36 |
| Dividend yield | 0.25% | 0.16% | 0.74% |
| FY26 operating cash flow (Rs Cr) | 5,526.37 | 43.57 | 910.50 |
Healthcare, chemicals and food earnings follow volumes, store additions and margins, so full-year numbers and quarterly trends together give a better view.
How to Evaluate Generic Drug Maker, Zinc Oxide and Basmati Stocks to Buy Before You Invest
A short checklist keeps the research consistent when you screen generic drug maker, zinc oxide and basmati stocks and shortlist generic drug maker, zinc oxide and basmati stocks to buy.
- Compare each stock’s P/E with its industry P/E, which differs by company here.
- Check revenue growth, operating margin and cash flow together.
- Check whether revenue growth is turning into profit growth, not only sales.
- Read operating cash flow against capital expenditure to see how growth is funded.
- Watch debt to equity and interest cover before sizing a position.
- Spread exposure across companies and business lines instead of one demand cycle.
Check the Univest Screener for live data on these generic drug maker, zinc oxide and basmati stocks
Risks to Consider Before Investing in Generic Drug Maker, Zinc Oxide and Basmati Stocks
- Consumer demand: Spending patterns can shift sales between quarters.
- Input costs: Changes in raw material prices can affect margins.
- Quarterly trends: A single weak quarter can change near-term earnings, so track results every quarter.
Download the Univest iOS App or Univest Android App to track Aurobindo Pharma, JG Chemicals and LT Foods live.
Final Take: Which Stock Has the Strongest Roadmap?
These three healthcare, chemicals and consumer stocks cover generic medicines, zinc oxide and basmati rice. Aurobindo Pharma leads on FY26 operating margin; JG Chemicals leads on Q1 FY27 revenue growth and Q1 FY27 net profit growth; LT Foods leads on FY26 revenue growth and return on equity.
Across generic drug maker, zinc oxide and basmati stocks, each roadmap still has to turn growth into steady profit, so independent research and position sizing matter. Investors should consult a SEBI-registered advisor before acting on any of the generic drug maker, zinc oxide and basmati stocks to buy discussed here.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Generic Drug Maker, Zinc Oxide and Basmati Stocks
Which are the best generic drug maker, zinc oxide and basmati stocks in India with a strong roadmap?
Ans. Aurobindo Pharma, JG Chemicals and LT Foods stand out for their roadmaps in generic medicines, zinc oxide and basmati rice. FY26 revenue growth was 5.6% at Aurobindo Pharma, 15.2% at JG Chemicals and 25.7% at LT Foods, and return on equity ranges from 9.25% to 13.83%.
Is Aurobindo Pharma a good stock to buy now?
Ans. Aurobindo Pharma has a debt to equity ratio of 0.21, a return on equity of 9.25% and a P/E of 25.46 against an industry P/E of 37.59. Valuation, demand and input costs move results. This article is not investment advice, so consult a SEBI-registered advisor before deciding.
What is the P/E ratio of Aurobindo Pharma, JG Chemicals and LT Foods?
Ans. The P/E ratio is 25.46 for Aurobindo Pharma (industry 37.59), 31.94 for JG Chemicals (industry 36.60) and 21.98 for LT Foods (industry 34.85). All of them trade below the industry multiple.
Which of these generic drug maker, zinc oxide and basmati stocks has the highest return on equity?
Ans. LT Foods has the highest return on equity at 13.83%, followed by JG Chemicals at 12.47% and Aurobindo Pharma at 9.25%.
What are the risks of investing in generic drug maker, zinc oxide and basmati stocks?
Ans. The main risks are consumer demand, input costs and quarterly trends. Spending patterns can shift sales between quarters.
How did Aurobindo Pharma, JG Chemicals and LT Foods perform in Q1 FY27?
Ans. Aurobindo Pharma reported revenue of Rs 9,414.58 crore, up 18.1% year on year, and net profit rose 25.2% to Rs 1,032.03 crore. JG Chemicals reported revenue of Rs 318.38 crore, up 43.8% year on year, and net profit rose 59.7% to Rs 26.12 crore. LT Foods reported revenue of Rs 3,161.29 crore, up 26.4% year on year, and net profit rose 8.9% to Rs 183.45 crore.
Do generic drug maker, zinc oxide and basmati stocks pay dividends?
Ans. Yes, all three companies pay dividends. The dividend yield is 0.25% for Aurobindo Pharma, 0.16% for JG Chemicals and 0.74% for LT Foods, based on dividends declared for FY26.
How can I invest in generic drug maker, zinc oxide and basmati stocks in India?
Ans. You can buy generic drug maker, zinc oxide and basmati stocks through a demat and trading account on NSE or BSE after checking each company’s financials, margins and valuation. The Univest Screener lets you compare fundamentals before placing an order. Investments in securities are subject to market risk, so consider your risk profile first.
